Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Execs Highlight Cosentyx, LCZ696 As Key 2015 Launches

This article was originally published in The Pink Sheet Daily

Executive Summary

The swapping of product portfolios with other companies remains on track at Switzerland’s big pharma Novartis, despite a seven-percentage-point sales erosion due to emerging generic competition during 2014, and more recent currency turmoil in its home country.

You may also be interested in...



Cardiovascular Agents Could Be The Heart Of 2015’s New Drug Class

Expect upheavals in the cardiovascular disease landscape in 2015 as FDA considers new drugs that could significantly change the management of chronic heart failure while payers brace for the introduction of PCSK9 inhibitors for hypercholesterolemia.

Cardiovascular Agents Could Be The Heart Of 2015’s New Drug Class

Expect upheavals in the cardiovascular disease landscape in 2015 as FDA considers new drugs that could significantly change the management of chronic heart failure while payers brace for the introduction of PCSK9 inhibitors for hypercholesterolemia.

EU Clears GSK-Novartis And Mylan-Abbott Deals, With Minor Conditions

Meningitis and tetanus-diphtheria vaccines and smoking cessation products will be divested by GSK in Europe, and B-Raf and MEK inhibitors by Novartis, while Mylan will divest four generics in five markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077818

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel